Top in endocrinology: COVID-19, irregular sleep linked to higher risk for diabetes
Children with presymptomatic type 1 diabetes who had COVID-19 experienced higher rates of type 1 diabetes diagnoses than those who did not have COVID-19, according to recently published data.
Researchers initially thought the increase during the pandemic was due to lockdowns, but the incidence rate of type 1 diabetes among children who did not have SARS-CoV-2 antibodies was similar to the incidence rate before the pandemic.
“Because we had been screening and following children in an early presymptomatic stage of type 1 diabetes for several years, we were able to look to see whether infection, and not just the lockdowns, modified the path to clinical diabetes,” Anette-Gabriele Ziegler, MD, director of the Institute of Diabetes Research at Helmholtz Munich, German Research Center for Environmental Health, told Healio. “Therefore, our finding that there was a faster progression to clinical type 1 diabetes since the pandemic and that this was predominantly seen in those children who had COVID-19 was indeed a surprising finding.”
It was the top story in endocrinology last week.
In another top story, adults whose sleep duration varies by more than 1 hour on average per night had a higher risk for developing diabetes, even among those with low genetic risk for the disease.
Read these and more top stories in endocrinology below:
COVID-19 increases type 1 diabetes rates for children with early-stage disease
Children with presymptomatic type 1 diabetes progressed more quickly to type 1 diabetes after having COVID-19, according to a research letter published in JAMA. Read more.
Irregular sleep duration may raise risk for developing diabetes
Adults with a sleep duration that varies by a mean of more than 1 hour each night may have an increased risk for developing diabetes, according to a study published in Diabetes Care. Read more.
FDA receives resubmitted NDA for sotagliflozin to treat type 1 diabetes and CKD
Lexicon Pharmaceuticals resubmitted a new drug application to the FDA for the drug sotagliflozin — marketed under the brand name Zynquista — as an adjunct to insulin therapy for adults with type 1 diabetes and chronic kidney disease. Read more.
Mayo Clinic tops list of best US hospitals for diabetes and endocrinology
The Mayo Clinic in Rochester, Minnesota, is again the No. 1 hospital in the United States for diabetes and endocrinology, according to the U.S. News & World Report’s 2024-2025 Best Hospitals rankings. Read more.
Lifestyle intervention lowers type 2 diabetes odds for men at high genetic risk
A lifestyle intervention program composed of a healthy diet and increased physical activity can reduce the risk for type 2 diabetes among men with high genetic risk for the disease, according to trial findings. Read more.